domains/health/behavioral-glp1-companion-programs-achieve-0-8-percent-weight-maintenance-post-discontinuation-versus-11-12-percent-regain-proving-standalone-behavioral-value.md

@@ -17,3 +17,10 @@ related: ["glp1-long-term-persistence-ceiling-14-percent-year-two", "comprehensi
 # Behavioral GLP-1 companion programs achieve 0.8 percent average weight change at one year post-discontinuation versus 11-12 percent regain in clinical trials proving standalone behavioral value
 
 Omada Health reports that members who discontinued GLP-1 receptor agonists but continued behavioral support showed 0.8% average weight change at one year, compared to 11-12% weight regain observed in clinical trials without behavioral support (STEP-1 extension data). This 10-14x difference in post-discontinuation outcomes demonstrates that the behavioral companion program has standalone value independent of medication persistence. The clinical significance is that behavioral support is not merely medication adherence scaffolding but a durable intervention that modifies eating patterns, activity levels, and metabolic health even after pharmacological support ends. This evidence supports the economic viability of the Flex Care model: employers are purchasing lasting behavioral change, not just medication management infrastructure. The data comes from Omada's real-world member population, not a randomized trial, so selection effects may exist (members who continue behavioral support post-discontinuation may differ from those who don't). However, the magnitude of the difference (0.8% vs. 11-12%) is large enough to suggest a genuine effect beyond selection. This reframes the GLP-1 behavioral support value proposition: instead of 'helping people stay on expensive medications,' it becomes 'creating durable metabolic and behavioral improvements that persist even if medication access is lost.' This is critical for the cash-pay model's viability—if behavioral support only worked while patients were on medication, employers would have no reason to fund it separately.
+
+
+## Supporting Evidence
+
+**Source:** WeightWatchers Med+ clinical data, May 2026
+
+WeightWatchers Med+ integrates board-certified clinician care, Weight Watchers Diabetes Support program with tailored nutrition guidance, coaching and community support (virtual and in-person), and blood sugar tracking tools. The 136-person study showed 0.75% HbA1c reduction after 6 months on the WW diabetes nutrition program, demonstrating measurable clinical outcomes from behavioral support infrastructure.

domains/health/glp1-managed-access-operating-systems-require-multi-layer-infrastructure-beyond-formulary.md

@@ -11,7 +11,7 @@ sourced_from: health/2026-04-28-glp1-managed-access-operating-systems-payer-infr
 scope: structural
 sourcer: on/healthcare.tech
 supports: ["glp1-payer-fiscal-unsustainability-10x-pmpm-increase-2023-2024", "digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring"]
-related: ["value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk", "glp1-payer-fiscal-unsustainability-10x-pmpm-increase-2023-2024", "glp1-long-term-persistence-ceiling-14-percent-year-two", "digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring", "glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035", "federal-glp1-expansion-programs-reproduce-access-hierarchy-at-design-level", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics"]
+related: ["value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk", "glp1-payer-fiscal-unsustainability-10x-pmpm-increase-2023-2024", "glp1-long-term-persistence-ceiling-14-percent-year-two", "digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring", "glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035", "federal-glp1-expansion-programs-reproduce-access-hierarchy-at-design-level", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics", "glp1-managed-access-operating-systems-require-multi-layer-infrastructure-beyond-formulary", "glp1-managed-access-infrastructure-creates-distinct-platform-opportunity-beyond-behavioral-coaching", "glp1-behavioral-mandate-rate-tripled-2024-2025-signaling-managed-access-infrastructure-shift"]
 ---
 
 # GLP-1 economics require managed-access operating systems beyond standard formulary because eligible population scale, cost structure, and multi-indication complexity demand continuous operational management across eligibility, behavioral gates, and discontinuation protocols
@@ -38,3 +38,10 @@ Indication expansion creates additional complexity requiring distinct medical-ne
 **Source:** PHTI December 2025 employer report
 
 PHTI identifies five specific infrastructure components: utilization management, outcomes-based contracting, indication-specific programs, adherence/discontinuation systems, and employer financing products. Three major payers (Evernorth 9M lives, Optum Rx, UHC) have operationalized distinct infrastructure plays. 79% of large employers expanded utilization management despite flat obesity-indication coverage.
+
+
+## Extending Evidence
+
+**Source:** WeightWatchers Med+ oral semaglutide program structure, May 2026
+
+WeightWatchers Med+ demonstrates a distinct infrastructure layer: branded-drug-only strategy (no compounded semaglutide), prior authorization navigation, utilization management support, and insurance coverage optimization ($25/month with pharmacy benefits). This differentiates WW from competitors who relied on compounding (Hims/Hers) and positions WW as a managed access platform for FDA-approved formulations across multiple delivery mechanisms (injectable and oral semaglutide).

inbox/archive/health/2026-05-01-weightwatchers-oral-semaglutide-post-bankruptcy-clinical-pivot.md

@@ -7,10 +7,13 @@ date: 2026-05-01
 domain: health
 secondary_domains: []
 format: press-release
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-02
 priority: medium
 tags: [WeightWatchers, GLP-1, oral-semaglutide, obesity, behavioral-health, atoms-to-bits, Belief-4]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content